KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to 0.61.

  • Neogenomics' Equity Ratio rose 1018.25% to 0.61 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.61, marking a year-over-year increase of 1018.25%. This contributed to the annual value of 0.55 for FY2024, which is 163.62% down from last year.
  • As of Q3 2025, Neogenomics' Equity Ratio stood at 0.61, which was up 1018.25% from 0.61 recorded in Q2 2025.
  • Neogenomics' Equity Ratio's 5-year high stood at 0.61 during Q2 2025, with a 5-year trough of 0.55 in Q4 2024.
  • Over the past 5 years, Neogenomics' median Equity Ratio value was 0.57 (recorded in 2023), while the average stood at 0.58.
  • As far as peak fluctuations go, Neogenomics' Equity Ratio crashed by 9747.3% in 2021, and later skyrocketed by 1018.25% in 2025.
  • Neogenomics' Equity Ratio (Quarter) stood at 0.59 in 2021, then decreased by 3.23% to 0.57 in 2022, then decreased by 2.36% to 0.56 in 2023, then decreased by 1.64% to 0.55 in 2024, then increased by 10.69% to 0.61 in 2025.
  • Its last three reported values are 0.61 in Q3 2025, 0.61 for Q2 2025, and 0.55 during Q1 2025.